Erik T. Engelson
Richard Narido previously served as our Vice President of Finance, a role he has held since March 2021. As Chief Financial Officer, Mr. Narido will serve as our principal financial officer and principal accounting officer. From July 2018 to March 2021, Mr. Narido served in various roles at Assembly Biosciences, Inc., including most recently the Executive Director, Finance, and Treasury. From June 2014 to June 2018, Mr. Narido served in various roles at Bio-Rad Laboratories, including Americas Head of Finance, Global Commercial Operations. Prior to that, Mr. Narido held various finance roles, including Global Head Finance Reporting and Accounting for Novartis Vaccines and Diagnostics Division and several positions including business unit Controller for McKesson Corporation. Mr. Narido started his career with PricewaterhouseCoopers’s Financial Audit and Assurance practice. Mr. Narido holds a Bachelor of Science degree from University of San Francisco and a Master of Science degree from Pepperdine Graziadio Business School.
Tony Allen has served as our Chief Operations Officer since September 2021. From May 2018 to September 2021, Mr. Allen served as Vice President and Head of Global Internal Manufacturing at Ortho-Clinical Diagnostics, Inc., an in vitro diagnostics company. Mr. Allen served as Vice President and General Manager at Gap Partners, Inc., a metal fabrication company, from March 2017 to May 2018, Global Senior Project Management Office Head at Alcon Inc., an eye care device company, from March 2016 to March 2017 and Vice President of Operations at Accriva Diagnostics Holdings, Inc., a medical equipment and supplies manufacturing company, from October 2015 to March 2016. Prior to that he served in various operations and leadership roles at DJO Global, Inc., an orthopedic medical device company, for approximately eight years and at NEC Computers International, an information technology and electronics company, for approximately nine years. Mr. Allen received a T5 in telecommunications and radio communications from the Department of Marine Radio and Radar, Limerick, Ireland and an Executive M.B.A. from Aberdeen University.
Kevin Collins has served as our Chief Revenue Officer Since May 2021. Mr. Collins has over 15 years of commercial leadership experience in the medical technology industry. Prior to Joining Lucira, Mr. Collins served as Vice President of International Commercial Operations and Head of Sales and Market Development at Outset Medical. Prior to joining Outset, Kevin spent 12 years at Intuitive Surgical where he served as the Vice President for the Global Distribution business unit. Mr. Collins earned a B.A. in Communications and Political Science from the University of Arizona.
Nadine Greiner, Ph.D. has served as our Chief Human Resources Officer since June, 2022. Nadine’s career has consisted of leading organizations through rapid growth and change. She has led the Human Resources function at private and public companies, and for capital ventures as well as for companies of over 15B in revenue. She has served as the head of Human Resources at the following: 4D Molecular Therapeutics, Sutter Health (California Pacific Medical Center and Palo Alto Medical Foundation), The Institute on Aging, Brown and Toland, Uplift Family Services, and globally in the Corporate Groups at Bank of America.
Nadine earned a dual doctorate in Organization Development and Clinical Psychology.
This home test kit has not been FDA cleared or approved. This home test kit has been authorized by FDA under EUA. This home test kit has been authorized only for the testing of nasal swabs for detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This home test kit is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of IVDs for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or revoked sooner.
These home tests have not been FDA cleared or approved. These home tests have been authorized by FDA under Emergency Use Authorization (EUA). These home tests have been authorized only for the testing of nasal swabs for detection of nucleic acid from SARS-CoV-2 alone, or from SARS-CoV-2, influenza A, and influenza B; not for any other viruses or pathogens. These home tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of IVDs for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or revoked sooner.
Monday -Friday 7:00am-5:00pm PT
© 2023 Lucira Health, Inc. All rights reserved.
US
Canada
